Navigation Links
MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
Date:12/4/2008

by T-lymphocytes, mast cells, and eosinophils involved in regulating the differentiation, proliferation, and activation of eosinophils via the IL-5 receptor, known as IL-5R. The IL-5R consists of an alpha chain and a beta chain. Expression of the IL-5R alpha chain is restricted largely to eosinophils, basophils, and some mast cells in humans. The alpha-chain exclusively binds IL-5 and the intracellular portion of IL-5Ralpha is involved in cellular activation. Thus, the IL-5R alpha.chain may be a good target for a therapeutic antibody in the management of asthma. Eosinophils, and perhaps basophils and some mast cells, can be preferentially targeted for antibody-dependent cell cytotoxicity through IL-5R alpha chain depleting cells thought to be key in disease pathogenesis and severity. In addition, blocking of IL-5R alpha could provide benefit by neutralizing effects of IL-5.

MedImmune's Clinical Development in Asthma

MedImmune has multiple approaches in development targeting asthma. Currently, in human testing, the company has antibodies targeting IL-9 and IL-13, in addition to the anti-IL-5R that is the subject of this press release.

About Asthma

Asthma is a chronic disease of the airways that may cause wheezing, breathlessness, chest tightness and coughing. According to the U.S. Centers for Disease Control and Prevention, more than 30 million Americans reported having a history of asthma in 2003, including nine million children. About 20 million said they currently had asthma. In 2000, the CDC reported that there were more than 10 million asthma-related outpatient visits to private physician offices and hospital clinics. The National Institutes of Health have estimated asthma-related healthcare costs in the U.S. at $14 billion annually.

About MedImmune

MedImmune is a leading, innovation-focused biotechnology company whose mission it is to provide better medic
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. MedImmune Announces Zook as President
2. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
3. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
4. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
5. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
6. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
7. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
8. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
9. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
10. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
11. Seneca Valley High School Student Receives Science Award From MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Other Biology Technology:The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 2The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 3The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 4The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 5The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 6The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 2The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 3The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 4The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 5Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 2Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 3Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 4Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 5Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 6Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 7Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 8Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 9Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 10
Breaking Biology News(10 mins):Delivering medicine directly into a tumor 2Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA 2Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 62407 1Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 62407 2Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 1Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 2Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 3Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 4Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 5Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 6Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 7Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 8Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 9Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 10Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 11Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 12Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 13Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 14Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 15Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 16Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 17Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 18Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 19Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 20Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 21Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 22Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 23Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 24Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 25Omnetics Announces Newest Addition to Nano Circular Family 62401 1Omnetics Announces Newest Addition to Nano Circular Family 62401 2